Intra-Cellular Therapies, Inc.
ITCI
Pozycja w akcjach
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Cena akcji
$131.87
Ostatnia synchronizacja: 2025-04-02
Kapitalizacja rynkowa
$12.68B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategoria
Healthcare
Wskaźnik P/B dla Intra-Cellular Therapies, Inc. (ITCI)
Wskaźnik P/B na dzień October 2026 TTM: 11.84
Według najnowszych raportów finansowych i ceny akcji Intra-Cellular Therapies, Inc., obecny wskaźnik P/B (TTM) wynosi 11.84. Na koniec 2023 wynosił 11.61.
Historia wskaźnika P/B dla Intra-Cellular Therapies, Inc. od 2013 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 11.84 | 57.89% |
| 2024 | 7.50 | -35.41% |
| 2023 | 11.61 | 53.06% |
| 2022 | 7.59 | -25.46% |
| 2021 | 10.18 | 198.75% |
| 2020 | 3.41 | -64.92% |
| 2019 | 9.71 | 395.06% |
| 2018 | 1.96 | 33.29% |
| 2017 | 1.47 | -15.32% |
| 2016 | 1.74 | -57.28% |
| 2015 | 4.07 | -3.03% |
| 2014 | 4.19 | -48.67% |
| 2013 | 8.17 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -57.43% |
IN
|
